Total Payments
$214,044
2024 Payments
$13,278
Companies
23
Transactions
689
Medicare Patients
176
Medicare Billing
$29,426
Payment Breakdown by Category
Other$169,008 (79.0%)
Consulting$24,384 (11.4%)
Food & Beverage$10,521 (4.9%)
Travel$7,331 (3.4%)
Research$2,447 (1.1%)
Education$352.66 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $169,008 | 102 | 79.0% |
| Consulting Fee | $24,384 | 5 | 11.4% |
| Food and Beverage | $10,521 | 542 | 4.9% |
| Travel and Lodging | $7,331 | 28 | 3.4% |
| Unspecified | $2,447 | 2 | 1.1% |
| Education | $352.66 | 10 | 0.2% |
Payments by Type
General
$211,597
687 transactions
Research
$2,447
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | $85,251 | 174 | $0 (2024) |
| Allergan, Inc. | $42,048 | 112 | $0 (2020) |
| Teva Pharmaceuticals USA, Inc. | $21,113 | 40 | $0 (2024) |
| ABBVIE INC. | $17,217 | 70 | $0 (2024) |
| Axsome Therapeutics, Inc. | $15,571 | 16 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $9,212 | 13 | $0 (2024) |
| Alkermes, Inc. | $8,066 | 30 | $0 (2024) |
| ITI, Inc. | $6,494 | 14 | $0 (2022) |
| Takeda Pharmaceuticals America, Inc. | $3,765 | 2 | $0 (2017) |
| F. Hoffmann-La Roche AG | $2,447 | 2 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $13,278 | 59 | Axsome Therapeutics, Inc. ($12,352) |
| 2023 | $17,411 | 31 | Otsuka America Pharmaceutical, Inc. ($7,596) |
| 2022 | $16,293 | 55 | Otsuka America Pharmaceutical, Inc. ($11,559) |
| 2021 | $39,619 | 101 | Otsuka America Pharmaceutical, Inc. ($12,343) |
| 2020 | $28,614 | 52 | Otsuka America Pharmaceutical, Inc. ($10,315) |
| 2019 | $30,930 | 128 | Otsuka America Pharmaceutical, Inc. ($16,388) |
| 2018 | $41,038 | 144 | Otsuka America Pharmaceutical, Inc. ($15,786) |
| 2017 | $26,862 | 119 | Otsuka America Pharmaceutical, Inc. ($11,226) |
All Payment Transactions
689 individual payment records from CMS Open Payments — Page 1 of 28
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Vanda Pharmaceuticals Inc. | FANAPT (Drug) | Food and Beverage | In-kind items and services | $23.01 | General |
| Category: SCHIZOPHRENIA | ||||||
| 12/17/2024 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug) | Food and Beverage | In-kind items and services | $25.01 | General |
| Category: Neuroscience | ||||||
| 12/11/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $22.51 | General |
| Category: PSYCHIATRY | ||||||
| 12/10/2024 | Takeda Pharmaceuticals U.S.A., Inc. | TRINTELLIX (Drug) | Food and Beverage | In-kind items and services | $15.08 | General |
| Category: NEUROSCIENCE | ||||||
| 11/27/2024 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $26.30 | General |
| Category: CNS | ||||||
| 11/26/2024 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Food and Beverage | In-kind items and services | $16.88 | General |
| Category: Neuroscience | ||||||
| 11/25/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $14.49 | General |
| Category: NEUROSCIENCE | ||||||
| 11/21/2024 | IRONSHORE PHARMACEUTICALS INC. | JORNAY PM (Drug) | Food and Beverage | Cash or cash equivalent | $24.12 | General |
| Category: CENTRAL NERVOUS SYSTEM STIMULANT | ||||||
| 11/14/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $20.53 | General |
| Category: Neuropsychiatry | ||||||
| 11/12/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $22.03 | General |
| Category: Central Nervous System | ||||||
| 11/06/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $19.05 | General |
| Category: PSYCHIATRY | ||||||
| 11/05/2024 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug) | Food and Beverage | In-kind items and services | $16.19 | General |
| Category: Neuroscience | ||||||
| 10/29/2024 | IRONSHORE PHARMACEUTICALS INC. | JORNAY PM (Drug) | Food and Beverage | Cash or cash equivalent | $21.99 | General |
| Category: CENTRAL NERVOUS SYSTEM STIMULANT | ||||||
| 10/23/2024 | Sage Therapeutics, Inc. | ZURZUVAE (Drug) | Food and Beverage | In-kind items and services | $19.13 | General |
| Category: PSYCHIATRY/PSYCHOLOGY | ||||||
| 10/22/2024 | Takeda Pharmaceuticals U.S.A., Inc. | TRINTELLIX (Drug) | Food and Beverage | In-kind items and services | $15.74 | General |
| Category: NEUROSCIENCE | ||||||
| 10/15/2024 | Alkermes, Inc. | LYBALVI (Drug), LYBALVI, LYBALVI | Food and Beverage | In-kind items and services | $22.13 | General |
| Category: CNS | ||||||
| 10/08/2024 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug) | Food and Beverage | In-kind items and services | $19.79 | General |
| Category: Neuroscience | ||||||
| 09/03/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $23.86 | General |
| Category: Central Nervous System | ||||||
| 08/29/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $15.68 | General |
| Category: PSYCHIATRY | ||||||
| 08/21/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $23.94 | General |
| Category: Neuropsychiatry | ||||||
| 08/20/2024 | IRONSHORE PHARMACEUTICALS INC. | JORNAY PM (Drug) | Food and Beverage | Cash or cash equivalent | $13.84 | General |
| Category: CENTRAL NERVOUS SYSTEM STIMULANT | ||||||
| 08/13/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $14.49 | General |
| Category: PSYCHIATRY | ||||||
| 08/07/2024 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $26.82 | General |
| Category: CNS | ||||||
| 07/24/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $19.27 | General |
| Category: PSYCHIATRY | ||||||
| 07/17/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $27.13 | General |
| Category: Central Nervous System | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| DEVELOPMENT OF A SHORT FORM OF THE NATIONAL EYE INSTITUTE VISUAL FUNCTION QUESTIONNAIRE-25 NEI VFQ-25 | F. Hoffmann-La Roche AG | $2,447 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 1 | 23 | 30 | $10,694 | $2,610 |
| 2022 | 2 | 51 | 145 | $41,569 | $12,039 |
| 2021 | 2 | 52 | 134 | $32,683 | $8,353 |
| 2020 | 2 | 50 | 124 | $30,354 | $6,424 |
Total Patients
176
Total Services
433
Medicare Billing
$29,426
Procedure Codes
7
All Medicare Procedures & Services
7 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 23 | 30 | $10,694 | $2,610 | 24.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 36 | 120 | $32,102 | $9,013 | 28.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 15 | 25 | $9,467 | $3,026 | 32.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 34 | 110 | $28,723 | $7,467 | 26.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 18 | 24 | $3,960 | $885.86 | 22.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 35 | 102 | $26,724 | $5,677 | 21.2% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 15 | 22 | $3,630 | $747.51 | 20.6% |
About Dr. Burton Singerman, MD
Dr. Burton Singerman, MD is a Psychiatry healthcare provider based in Johnstown, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/30/2005. The National Provider Identifier (NPI) number assigned to this provider is 1003813452.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Burton Singerman, MD has received a total of $214,044 in payments from pharmaceutical and medical device companies, with $13,278 received in 2024. These payments were reported across 689 transactions from 23 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($169,008).
As a Medicare-enrolled provider, Singerman has provided services to 176 Medicare beneficiaries, totaling 433 services with total Medicare billing of $29,426. Data is available for 4 years (2020–2023), covering 7 distinct procedure/service records.
Ad
Practice Information
- Specialty Psychiatry
- Location Johnstown, PA
- Active Since 06/30/2005
- Last Updated 02/06/2009
- Taxonomy Code 2084P0800X
- Entity Type Individual
- NPI Number 1003813452
Products in Payments
- REXULTI (Drug) $72,284
- VRAYLAR (Drug) $59,246
- AUSTEDO (Drug) $18,453
- Auvelity (Drug) $15,571
- ABILIFY MAINTENA (Drug) $13,650
- Trintellix (Drug) $12,734
- CAPLYTA (Drug) $6,508
- UZEDY (Drug) $2,265
- LATUDA (Drug) $424.61
- INVEGA TRINZA (Drug) $369.15
- ARISTADA (Drug) $338.75
- INGREZZA (Drug) $218.30
- INVEGA SUSTENNA (Drug) $205.00
- Entyvio (Biological) $196.20
- HETLIOZ (Drug) $184.73
- TRINTELLIX (Drug) $168.15
- LYBALVI (Drug) $147.46
- BRINTELLIX (Drug) $103.70
- Austedo XR (Drug) $101.18
- JORNAY PM (Drug) $87.10
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.